Targeted Fe-doped silica nanoparticles as a novel ultrasound–magnetic resonance dual-mode imaging contrast agent for HER2-positive breast cancer

References

• AndersonWFHow many etiological subtypes of breast cancer: two, three, four, or more?Breast Dis A Year Book Q2015264296297
   Google Scholar
• Von MinckwitzGProcterMDe AzambujaEAdjuvant pertuzumab and trastuzumab in early HER2-positive breast cancerN Engl J Med2017377212213128581356
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• SwainSMBaselgaJKimSBPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerN Engl J Med2015372872473425693012
   PubMed Web of Science ®Google Scholar
• WolffACHammondMEAllisonKHHarveyBEMcShaneLMDowsettMHER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update SummaryJ Oncol Pract201814743744129920138
   PubMed Web of Science ®Google Scholar
• RakhaEAPinderSEBartlettJMUpdated UK recommendations for HER2 assessment in breast cancerJ Clin Pathol2015682939925488926
   PubMed Web of Science ®Google Scholar
• LiedtkeCJackischCThillMAGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2018Breast Care201813319620830069181
   PubMedGoogle Scholar
• GradisharWJAndersonBOBalassanianRBreast cancer, version 4.2017, NCCN clinical practice guidelines in oncologyJ Natl Compr Canc Netw201816331032029523670
   PubMed Web of Science ®Google Scholar
• WanCDuJFangHLiFWangLEvaluation of breast lesions by contrast enhanced ultrasound: qualitative and quantitative analysisEur J Radiol2012814e444e45021612882
   PubMed Web of Science ®Google Scholar
• StanzaniDChalaLFBarrosNDCerriGGChammasMCCan Doppler or contrast-enhanced ultrasound analysis add diagnostically important information about the nature of breast lesions?Clinics2014692879224519198
   PubMedGoogle Scholar
• SzymanskiMSochaMWKowalkowskaMEDifferentiating between benign and malignant adnexal lesions with contrast-enhanced transvaginal ultrasonographyInt J Gynaecol Obstet2015131214715126254725
   PubMedGoogle Scholar
• KostopoulosSAVassiouKGLavdasENComputer-based automated estimation of breast vascularity and correlation with breast cancer in DCE-MRI imagesMagn Reson Imaging201735394527569368
   PubMedGoogle Scholar
• ChangRFChenHHChangYCQuantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRIMagn Reson Imaging201634680981926968141
   PubMed Web of Science ®Google Scholar
• YangHCaiWXuLNanobubble–Affibody: novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumorBiomaterials20153727928825453958
   PubMed Web of Science ®Google Scholar
• LiJAnYLZangFCA dual mode targeting probe for distinguishing HER2-positive breast cancer cells using silica-coated fluorescent magnetic nanoparticlesJ Nanoparticle Res201315101980
   Google Scholar
• XuSYangFZhouXUniform PEGylated PLGA microcapsules with embedded Fe3O4 nanoparticles for US/MR dual-modality imagingACS Appl Mater Interfaces2015736204602046826327472
   PubMed Web of Science ®Google Scholar
• WangYCaiDWuHFunctionalized Cu3 BiS3 nanoparticles for dual-modal imaging and targeted photothermal/photodynamic therapyNanoscale20181094452446229451575
   PubMedGoogle Scholar
• BrandWNoorlanderCWGiannakouCNanomedicinal products: a survey on specific toxicity and side effectsInt J Nanomedicine2017126107612928883724
   PubMed Web of Science ®Google Scholar
• KhatriMBelloDPalAKEvaluation of cytotoxic, genotoxic and inflammatory responses of nanoparticles from photocopiers in three human cell linesPart Fibre Toxicol20131014223968360
   PubMedGoogle Scholar
• DhawanASharmaVToxicity assessment of nanomaterials: methods and challengesAnal Bioanal Chem2010398258960520652549
   PubMed Web of Science ®Google Scholar
• YanYFuJWangTLuXControlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticlesActa Biomater201751347147828131940
   PubMedGoogle Scholar
• DoadrioALSánchez-MonteroJMDoadrioJCSalinasAJVallet- RegíMMesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypillEur J Pharm Sci2017971827818251
   PubMed Web of Science ®Google Scholar
• MoJHeLMaBChenTTailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood-brain barrierACS Appl Mater Interfaces20168116811682526911360
   PubMedGoogle Scholar
• Pohaku MitchellKKLibermanAKummelACTroglerWCIron(III)-doped, silica nanoshells: a biodegradable form of silicaJ Am Chem Soc201213434139971400322871140
   PubMedGoogle Scholar
• YuLChenYWuM“Manganese extraction” strategy enables tumor-sensitive biodegradability and theranostics of nanoparticlesJ Am Chem Soc2016138319881989427441571
   PubMed Web of Science ®Google Scholar
• YecCCZengHCNanobubbles within a microbubble: synthesis and self-assembly of hollow manganese silicate and its metal-doped derivativesACS Nano2014866407641624878224
   PubMedGoogle Scholar
• YaoKXZengHCSimultaneous chemical modification and structural transformation of Stöber silica spheres for integration of NanocatalystsChem Mater2012241140148
   Google Scholar
• GretaJEgleDMariusSAccumulation and toxicity of superpara-magnetic iron oxide nanoparticles in cells and experimental animalsInt J Mol Sci20161781193
   PubMedGoogle Scholar
• ChanWTLiuCCChiang ChiauJSIn vivo toxicologic study of larger silica nanoparticles in miceInt J Nanomedicine2017123421343228496319
   PubMed Web of Science ®Google Scholar
• AbbarajuPLJambhrunkarMYangYAsymmetric mesoporous silica nanoparticles as potent and safe immunoadjuvants provoke high immune responsesChem Commun2018541620202023
   PubMed Web of Science ®Google Scholar
• CroissantJGFatieievYAlmalikAKhashabNMMesoporous silica and Organosilica nanoparticles: physical chemistry, biosafety, delivery strategies, and biomedical applicationsAdv Healthc Mater2018741700831
   Web of Science ®Google Scholar
• MendesLPDelgadoJMFCostaADBiodegradable nanoparticles designed for drug delivery: the number of nanoparticles impacts on cytotoxicityToxicol In Vitro20152961268127425596133
   PubMed Web of Science ®Google Scholar
• DingNSanoKKanazakiKIn vivo HER2-targeted magnetic resonance tumor imaging using iron oxide nanoparticles conjugated with anti-HER2 fragment antibodyMol Imaging Biol201618687087627351762
   PubMedGoogle Scholar
• LibermanAWuZBarbackCVHollow iron-silica nanoshells for enhanced high intensity focused ultrasoundJ Surg Res2014190239139824972734
   PubMedGoogle Scholar
• YangZLuoHCaoZDual-targeting hybrid nanoparticles for the delivery of SN38 to HER2 and CD44 overexpressed human gastric cancerNanoscale2016822115431155827203688
   PubMed Web of Science ®Google Scholar
• ZhangNCaiXGaoWA multifunctional theranostic Nanoagent for dual-mode image-guided HIFU/Chemo-synergistic cancer therapyTheranostics20166340441726909114
   PubMedGoogle Scholar
• JiRLiXZhouCIdentifying macrophage enrichment in atherosclerotic plaques by targeting dual-modal us imaging/MRI based on biodegradable Fe-doped hollow silica nanospheres conjugated with anti-CD68 antibodyNanoscale20181043202462025530361722
   PubMedGoogle Scholar